David E. Hamaoui

Array ( [id] => 18013328 [patent_doc_number] => 11505610 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Compositions and methods comprising anti-NRP2 antibodies [patent_app_type] => utility [patent_app_number] => 16/376979 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 49 [patent_no_of_words] => 61706 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178383 [patent_doc_number] => 11155618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Anti-TREM-1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/371964 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 34 [patent_no_of_words] => 32913 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17164145 [patent_doc_number] => 11150237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Patient-specific biomarkers of [patent_app_type] => utility [patent_app_number] => 16/371935 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4206 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868107 [patent_doc_number] => 20190284295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => Antibodies That Bind CD39 and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/352589 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243525 [patent_doc_number] => 20210363268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => Antibodies That Bind CD39 and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/980271 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435465 [patent_doc_number] => 20200031916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/298117 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16627506 [patent_doc_number] => 20210046159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => IL-1 ANTAGONIST AND TOXICITY INDUCED BY CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/978897 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778069 [patent_doc_number] => 20190263932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => ANTI-TRKA ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/281227 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253529 [patent_doc_number] => 20200262903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => Treatment of age-related macular degeneration [patent_app_type] => utility [patent_app_number] => 16/501058 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16501058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385621 [patent_doc_number] => 20220033473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN [patent_app_type] => utility [patent_app_number] => 16/479068 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656011 [patent_doc_number] => 20210052647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 [patent_app_type] => utility [patent_app_number] => 16/964796 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14621845 [patent_doc_number] => 20190224290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => Combination Therapy Utilizing P2X7 Peptides [patent_app_type] => utility [patent_app_number] => 16/268344 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16268344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931773 [patent_doc_number] => 12304970 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus [patent_app_type] => utility [patent_app_number] => 16/967110 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12208 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421278 [patent_doc_number] => 11254720 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Methods and systems for designing and/or characterizing soluble lipidated ligand agents [patent_app_type] => utility [patent_app_number] => 16/245472 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 42837 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16245472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185329 [patent_doc_number] => 20190112369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => USE OF IL-31RA MONOCLONAL ANTIBODIES FOR ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS [patent_app_type] => utility [patent_app_number] => 16/227307 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213975 [patent_doc_number] => 20190119372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => USE OF IL-31 MONOCLONAL ANTIBODIES FOR ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS [patent_app_type] => utility [patent_app_number] => 16/227266 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16227266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688369 [patent_doc_number] => 20210070845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => ANTI-CCT5 BINDING MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/771954 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17681026 [patent_doc_number] => 11365265 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Anti-C5 antibody combinations and uses thereof [patent_app_type] => utility [patent_app_number] => 16/217290 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 22 [patent_no_of_words] => 19184 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605983 [patent_doc_number] => 10906975 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) [patent_app_type] => utility [patent_app_number] => 16/209627 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 28602 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16209627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072333 [patent_doc_number] => 20190085054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/209239 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16209239 [rel_patent_id] =>[rel_patent_doc_number] =>)